Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-MEN 010: Pomalidomide + dexamethasone ± bortezomib in relapsed/refractory multiple myeloma
jRCTs031180315Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Overall response rate after 4 cycles of pomalidomide + dexamethasone. Started Apr 2019; status: completed.
02
Drugs
pomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs031180315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180315.